Pfizer AGM: Shareholders Reject Independent Chair Proposal as Bourla Touts 2025 Gains and Pipeline

Pfizer (NYSE:PFE) used its 2026 annual meeting of shareholders to highlight recent operational performance, outline strategic ...
PharmExec

Pfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliff

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...
Fierce Pharma

Pfizer's strategy head Andrew Baum to step down following brief tenure: reports

Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...
AOL

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...

Pfizer’s top strategy executive is leaving the company

Pfizer (PFE) stock is in focus as executive Andrew Baum, who joined the company in 2024 as the Chief Strategy and Innovation ...
Hosted on MSN

Pfizer CEO Albert Bourla’s best leadership advice: Being optimistic is better than being right

As the CEO of Pfizer, Albert Bourla led the team behind one of the most consequential medical breakthroughs of the modern era: the COVID-19 vaccine that saved millions of lives. Yet the leadership ...
STAT

Former banker brought on to revitalize Pfizer’s strategy departs his post

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...